Is platinib suitable for all lung cancer patients? What are the restrictions

Pralsetinib is an oral tyrosine kinase inhibitor that targets RET gene rearrangement (RET fusion) and is mainly used to treat non-small cell lung cancer (NSCLC) patients with RET fusion mutations. However, not all lung cancer patients are suitable for platinib treatment, and there are obvious gene-specific limitations to its use. RET fusion mutations only account for about 1% of the total cases of non-small cell lung cancer and are a relatively rare molecular subtype. Therefore, the therapeutic indications of platinib are limited to this type of RET-positive patients. Before use, it must be confirmed through genetic testing technology whether the patient carries a RET fusion mutation. Platinib is considered potentially effective only when such molecular changes are clearly present.

In addition to the prerequisites of gene mutation, the patient's systemic condition, previous treatment history, organ function status, etc. are also key factors affecting the applicability of platinib. For example, use may not be recommended in patients with severe hepatic or renal impairment, or those taking medications that may cause serious drug interactions. In addition, although platinib has been approved for RET-positive advanced NSCLC in many countries, it is still in the clinical trial stage or has not received formal approval in some regions. Therefore, its clinical use is still subject to drug availability and regulatory policies.

It is particularly important to point out thatDetection of RET mutations is still not popular in some areas of the country, and many patients may have missed the opportunity for targeted treatment because they did not receive comprehensive genetic testing. Therefore, it is of great significance to strengthen the awareness of molecular pathology testing and establish a standard process for RET testing to promote the clinical value of platinib. In short, platinib is not suitable for all patients with lung cancer. Instead, the biomarker of RET fusion mutation needs to be clarified in order to provide patients with a more precise and personalized treatment plan.

Reference: https://gavreto.com/